Clinical Trial Update: Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and efficacy of Xalatan delivered by a conventional dropper bottle versus a delivery device was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Xalatan (latanoprost)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Status: WITHDRAWN